Advertisement
News
Advertisement

Accelrys Fast-tracks Scientific Innovation with Modeling and Simulation Software Release

Tue, 06/19/2012 - 11:32pm
Bio-Medicine.Org

BRUSSELS, June 20, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, today announced the release of Accelrys Discovery Studio® 3.5 modeling and simulation software during the company's European Science Symposium in Brussels. The latest release extends Discovery Studio's portfolio of small-molecule ligand design and market-leading biological simulation tools, including a new, validated ligand-profiling database for drug repurposing studies, new science to assess the development potential of putative biologics and many additional enhancements that help deliver a highly effective life sciences modeling and simulation environment.

New, validated science built upon active, ongoing partnerships is the keystone underlying the latest Discovery Studio 3.5 release. Discovery Studio's new ligand-profiling solution uses a spatial aggregation propensity algorithm and Developability Index licensed from the Massachusetts Institute of Technology (MIT) and validated in collaboration with Novartis Pharma AG. Capabilities such as these provide important indicators of whether ligands and proteins will be good candidates for downstream development.

"The current economic squeeze on scientific resources across industries is counterbalanced by a continuing critical need for scientific innovation and excellence," said Senior Vice President and Chief Technology Officer Dr. Matt Hahn. "Deploying Discovery Studio modeling and simulation software on the scientifically aware Accelrys Enterprise Platform can help organizations meet the critical performance, cost and innovation goals that define today's increasingly information-driven R&D environments."

Discovery St

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading